Hydrothermal Alkaline Treatment (HALT) of Foam Fractionation Concentrate Derived from PFAS-Contaminated Groundwater
Environmental Science & Technology · 07.11.2023 · 57 (44) · 17154-17165
DOI: 10.1021/acs.est.3c05140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental Science & Technology, online erschienen am 19.10.2023. Verfasst von Shilai Hao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Civil and Environmental Engineering, Colorado School of Mines, Golden, Colorado 80401, United States. Hauptthemen laut MEDLINE: Water Pollutants, Chemical, Fluorocarbons, Groundwater. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Strategic Environmental Research and Development Program.
Abstract (Originalsprache)
While foam fractionation (FF) process has emerged as a promising technology for removal of per- and polyfluoroalkyl substances (PFASs) from contaminated groundwater, management of the resulting foam concentrates with elevated concentrations of PFASs (e.g., >1 g/L) remains a challenge. Here, we applied hydrothermal alkaline treatment (HALT) to two foam concentrates derived from FF field demonstration projects that treated aqueous film-forming foam (AFFF)-impacted groundwater. Results showed >90% degradation and defluorination within 90 min of treatment (350 °C, 1 M NaOH) of all 62 PFASs (including cations, anions, and zwitterions) identified in foam concentrates. Observed rate constants for degradation of individual perfluoroalkyl sulfonates (PFSAs, CnF2n+1-SO3-), the most recalcitrant class of PFASs, in both foam concentrates were similar to values measured previously in other aqueous matrices, indicating that elevated initial PFAS concentrations (e.g., PFHxSinit = 0.55 g/L), dissolved organic carbon (DOC; up to 4.5 g/L), and salt levels (e.g., up to 325 mg/L chloride) do not significantly affect PFAS reaction kinetics. DOC was partially mineralized by treatment, but a fraction (∼15%) was recalcitrant. Spectroscopic characterization revealed molecular features of the HALT-recalcitrant DOC fraction, and nontarget high-resolution mass spectrometry tentatively identified 129 nonfluorinated HALT-recalcitrant molecules. Analysis of process energy requirements shows that treating PFAS-contaminated foam concentrates with HALT would add minimally (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Civil and Environmental Engineering, Colorado School of Mines, Golden, Colorado 80401, United States.
- Department of Chemistry, Oregon State University, Corvallis, Oregon 97331, United States.
- Department of Agronomy, Purdue University, West Lafayette , Indiana 47907, United States.
- Thermo Fisher Scientific, San Jose, California 95134, United States.
ORCID-Profile: Shilai Hao, Youn Jeong Choi, Chuhui Zhang, Christopher P Higgins, Timothy J Strathmann
Förderung
- Strategic Environmental Research and Development Program
Zitieren
APA
Hao, S., Reardon, P. N., Choi, Y. J., Zhang, C., Sanchez, J. M., Higgins, C. P., & Strathmann, T. J. (2023). Hydrothermal Alkaline Treatment (HALT) of Foam Fractionation Concentrate Derived from PFAS-Contaminated Groundwater. Environmental Science & Technology, 57(44), 17154-17165. https://doi.org/10.1021/acs.est.3c05140
Vancouver
Hao S, Reardon PN, Choi YJ, Zhang C, Sanchez JM, Higgins CP, et al. Hydrothermal Alkaline Treatment (HALT) of Foam Fractionation Concentrate Derived from PFAS-Contaminated Groundwater. Environmental Science & Technology. 2023;57(44):17154-17165. doi:10.1021/acs.est.3c05140
BibTeX
@article{Hao2023,
author = {Hao, Shilai and Reardon, Patrick N and Choi, Youn Jeong and Zhang, Chuhui and Sanchez, Juan Moises and Higgins, Christopher P and Strathmann, Timothy J},
title = {Hydrothermal Alkaline Treatment (HALT) of Foam Fractionation Concentrate Derived from PFAS-Contaminated Groundwater},
journal = {Environmental Science & Technology},
year = {2023},
volume = {57},
number = {44},
pages = {17154--17165},
doi = {10.1021/acs.est.3c05140}
}
EUVIMED